Boosting antibody therapy with complement

Blood

Volumn 119, Issue 25, 2012, Pages 5945-5947

  Boross, Peter ^a   Leusen, Jeanette H W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN FC FRAGMENT;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; COMPLEMENT ACTIVATION; HUMAN; IMMUNOTHERAPY; IN VIVO STUDY; NONHUMAN; NOTE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84862744077     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-420760     Document Type: Note

References (7)

1. Elvington M, Huang Y, Morgan BP, et al. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012;119(25):6043-6051.
2. Gelderman KA, Tomlinson S, Ross GD, Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trends Immunol. 2004;25(3):158-164. (Pubitemid 38249490)
3. Kennedy AD, Solga MD, Schuman TA, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood. 2003;101(3):1071-1079. (Pubitemid 36139381)
4. Peng W, Zhang X, Mohamed N, et al. A deimmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation. Cancer Immunol Immunother. 2005;54(12):1172-1179. (Pubitemid 41416949)
5. Imai M, Ohta R, Varela JC, Song H, Tomlinson S. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement. Cancer Res. 2007;67(19):9535-9541. (Pubitemid 47535944)
6. Imai M, Landen C, Ohta R, Cheung NK, Tomlinson S. Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer. Cancer Res. 2005;65(22):10562-10568. (Pubitemid 41743751)
7. Boross P, Jansen JH, de Haij S, et al. The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. 2011;96(12):1822-1830.